Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    IDEAYA Biosciences Inc.

    NASDAQ: IDYA · Real-Time Price · USD
    20.52
    -0.41 (-1.96%)
    At close: May 05, 2025, 3:59 PM
    19.56
    -4.70%
    After-hours: May 05, 2025, 07:58 PM EDT
    -1.96%
    Bid 19.56
    Market Cap 1.8B
    Revenue (ttm) 7M
    Net Income (ttm) -274.48M
    EPS (ttm) -3.36
    PE Ratio (ttm) -6.11
    Forward PE -7.21
    Analyst Buy
    Ask 20.52
    Volume 1,301,506
    Avg. Volume (20D) 1,440,199.6
    Open 20.78
    Previous Close 20.93
    Day's Range 20.43 - 21.13
    52-Week Range 13.45 - 44.42
    Beta 0.51

    About IDYA

    IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, ...

    [Read more]
    Industry Biotechnology
    Sector Healthcare
    IPO Date May 23, 2019
    Employees 131
    Stock Exchange NASDAQ
    Ticker Symbol IDYA
    Website https://www.ideayabio.com
    Full Company Profile

    Analyst Forecast

    According to 13 analyst ratings, the average rating for IDYA stock is "Buy." The 12-month stock price forecast is $53, which is an increase of 158.22% from the latest price.

    Stock Forecasts

    Next Earnings Release

    IDEAYA Biosciences Inc. is scheduled to release its earnings on May 16, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    6 months ago
    +0.34%
    IDEAYA Biosciences shares are trading higher after... Unlock content with Pro Subscription
    10 months ago
    -3.37%
    IDEAYA Biosciences shares are trading lower after the company priced a $263 million public offering of 228,572 common shares and pre-funded warrants at $35 per share.
    news image

    2 weeks ago · seekingalpha.com

    Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later

    IDEAYA Biosciences' valuation has declined over 50% since mid-2024, prompting a re-evaluation of its investment potential. The most advanced program, darovasertib, targets tumors with GNAQ/GNA11 mutat...

    news image

    1 month ago · seekingalpha.com

    Why Ideaya Biosciences Is Down Despite Many Positives

    Ideaya Biosciences, Inc.'s stock has plummeted ~50% due to macroeconomic factors, Trump administration policies, and specific company challenges, impacting the entire biopharma sector. Trump's FDA pol...

    news image

    2 months ago · zacks.com

    Down -8.63% in 4 Weeks, Here's Why You Should You Buy the Dip in IDEAYA Biosciences (IDYA)

    The heavy selling pressure might have exhausted for IDEAYA Biosciences (IDYA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ...

    news image

    2 months ago · zacks.com

    IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss

    IDEAYA Biosciences, Inc. (IDYA) came out with a quarterly loss of $1.49 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $0.52 per share a year ago.

    news image

    2 months ago · seekingalpha.com

    Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study Coming

    Ideaya Biosciences, Inc.'s darovasertib + crizotinib combination is being explored in the potential registration-enabling phase 2/3 study targeting patients with 1st-line HLA-A2-negative metastatic uv...

    news image

    2 months ago · zacks.com

    All You Need to Know About IDEAYA Biosciences (IDYA) Rating Upgrade to Buy

    IDEAYA Biosciences (IDYA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

    Add to Watchlist